Anavex Life Sciences (AVXL) Non Operating Income (2016 - 2025)

Anavex Life Sciences (AVXL) has 10 years of Non Operating Income data on file, last reported at $1.1 million in Q4 2025.

• For the quarter ending Q4 2025, Non Operating Income fell 24.44% year-over-year to $1.1 million; the trailing twelve-month figure through Dec 2025 stood at $4.7 million (down 45.7% YoY), and the FY2025 full-year result was $5.0 million, down 49.05% from the prior year.
• Non Operating Income improved to $1.1 million in Q4 2025, from $1.0 million in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $2.8 million in Q4 2023 to a low of $179800.0 in Q2 2022.
• A 5-year average of $1.5 million and a median of $1.2 million in 2021 frame the typical range for Non Operating Income.
• Across the five-year window, Non Operating Income plunged 85.7% in 2022 and jumped 1174.75% in 2023, its largest moves.
• Tracing AVXL's Non Operating Income over 5 years: stood at $871003.0 in 2021, then jumped by 174.63% to $2.4 million in 2022, then grew by 15.22% to $2.8 million in 2023, then plunged by 46.26% to $1.5 million in 2024, then fell by 24.44% to $1.1 million in 2025.
• Business Quant data shows AVXL's Non Operating Income at $1.1 million in Q4 2025, $1.0 million in Q3 2025, and $1.2 million in Q2 2025.